|By PR Newswire||
|February 3, 2014 12:30 PM EST||
SYDNEY, Feb. 3, 2014 /PRNewswire/ -- Novogen Limited (ASX: NRT; NASDAQ: NVGN), an oncology drug development company, today announced the appointments of Justine Stehn, PhD and Professor Peter Gunning, PhD to roles within the Company. Dr. Stehn and Professor Gunning are the co-inventors of the anti-tropomyosin (ATM) drug technology platform that Novogen acquired in 2013, and their appointments are an important step in realizing the significant potential of this new drug platform in treating cancer.
Novogen is focused on developing two drug technology platforms: (i) ATMs as a safer and more effective alternative to taxane chemotherapy, and (ii) its proprietary platform of super-benzopyrans, a group of small molecules with high efficacy against the full breadth of cells within a tumor, including the cancer stem cells, which have been resistant to drugs and radiation up to this point.
Dr. Stehn will hold the position of Director, ATM Program, and will have full oversight over the progress of this technology into the clinic in 2015. Professor Gunning will join the Company's Scientific Advisory Panel for ATM Technology.
"I am extremely pleased to join Novogen at a crucial period in the company's development," said Dr. Stehn. "The work we have conducted thus far in understanding ATMs leads us to believe we may have discovered a new approach to cancer therapy that could potentially offer patients a safer and more effective alternative to traditional chemotherapy, but the commonly-used taxane drugs in particular. I look forward to transitioning my work in academic research to Novogen and joining a team that is dedicated to developing new cost-effective approaches to many of the most lethal forms of cancer."
Dr. Stehn and Professor Gunning made a significant breakthrough when they discovered that the microfilament components of the cytoskeleton of cancer cells are made up largely of a particular isoform of the protein tropomyosin known as Tm5NM1. Elimination of Tm5NM1 significantly impacted the growth and survival of the cancer cell without adversely effecting normal tissue.
The first generation of drug directed against this isoform resulted in a significant anti-tumor effect in animals with human tumor xenografts (melanoma, neuroblastoma), without the collateral toxicity seen with previous compounds targeting the actin microfilaments. Their work was featured on the cover of the August (2013) edition of the journal, Cancer Research.
"I've dedicated my life's work to researching the cytoskeleton and developing treatments for children afflicted with cancer. I'm excited to become a part of Novogen as the Company moves this promising technology into the clinic in neuroblastoma, the most prevalent solid tumor in children. It is a great bonus that these drugs are likely to be equally effective against adult cancers such melanoma, ovarian and prostate cancer," said Professor Gunning.
During 2014, Novogen expects to file up to four Investigational New Drug (IND) applications with the U.S. Food and Drug Administration for its ATM technology, enabling the company to start clinical trials in 2015.
Prior to joining Novogen, Dr. Stehn was Drug Development Coordinator and group leader of the Anti-Tropomyosin Drug Development Group in Prof Gunning's Oncology Research Unit in the School of Medical Sciences at the University of New South Wales. She received her PhD from the Garvan Institute of Medical Research in 2000. She was awarded a prestigious National Health and Medical Research Council (NHMRC) CJ Martin Fellowship to support her postdoctoral positions at Harvard University and the Centre for Cancer Research at the Massachusetts Institute of Technology (MIT).
Prof. Gunning has published more than 140 research papers, and his research focuses on diseases of childhood, primarily cancer and muscle damage. He completed his PhD at Monash University on gene expression in the nervous system, and then spent nine years at Stanford University working first on neuronal differentiation and then on the regulation of the genes responsible for specifying the structure of muscle. His research group discovered that tropomyosins are used to specify the spatial and temporal properties of the cell cytoskeleton in all cells of the body.
Graham Kelly, Ph.D., Novogen Executive Director and Chief Executive Officer, said, "We are privileged to have the two inventors of this drug technology join us, and provide a considerable boost to our goal of entering the clinic with a lead candidate compound in early 2015. Their intimate knowledge of the technology, combined with our drug development experience is a very strong combination that will help us in our goal of finding new and highly effective approaches to treat many of the world's most deadly cancers."
About Anti-Tropomyosin (ATM) Drugs
ATM drugs target the tropomyosin protein component of actin microfilaments. Microfilaments, along with microtubules, form the bulk of a cell's cytoskeleton, a largely invisible structure that allows the cell to communicate internally and with neighboring cells, to move, to adhere to other cells, and to divide. Drugs targeting the cytoskeleton (micro tubular component) have been among the most widely-used drugs in oncology for over 30 years and include taxes (paclitaxel, docetaxel) and vinca alkaloids (vincristine, vinblastine). However, the range of tumor types sensitive to these drugs is limited and their action is not limited to cancer cells, with resulting dose-limiting toxicity involving the gut, bone marrow and nerves.
Novogen ATM drugs have been designed to target the Tm5NM1 isoform of tropomyosin specifically. To date, cell types such as melanoma and neuroblastoma that have a high degree of inherent insensitivity to anti-microtubular drugs (e.g. taxanes), have proved highly sensitive to ATM drugs.
About Novogen Limited
Novogen is a public, Australian biotechnology company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Company is based in Sydney, Australia, and with a U.S. office in New Haven, Connecticut. The Company has two main drug technology platforms known as super-benzopyrans (SBP) and anti-tropomyosins (ATM). SBP drugs target cancer stem cells and are being developed for the treatment of ovarian cancer and glioblastoma. ATM drugs target the cancer cell cytoskeleton and are being developed for the treatment of melanoma, prostate cancer, ovarian cancer and neuroblastoma. Novogen has entered into a joint venture with Yale University known as CanTx Inc. with the aim of developing personalized chemotherapy for patients with ovarian cancer.
Further information is available on the Company's website, www.novogen.com.
16-20 Edgeworth David Ave, Hornsby NSW 2077 AUSTRALIA
P.O. Box 2333 Hornsby Westfield NSW 1635 AUSTRALIA
 Cancer Res 73, 5169-5182 (2013). Justine R. Stehn et al. A Novel Class of Anticancer Compounds Targets the Actin Cytoskeleton in Tumor Cells.
SOURCE Novogen Limited
If you’re responsible for an application that depends on the data or functionality of various IoT endpoints – either sensors or devices – your brand reputation depends on the security, reliability, and compliance of its many integrated parts. If your application fails to deliver the expected business results, your customers and partners won't care if that failure stems from the code you developed or from a component that you integrated. What can you do to ensure that the endpoints work as expect...
Sep. 24, 2016 04:30 PM EDT Reads: 1,469
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
Sep. 24, 2016 04:30 PM EDT Reads: 1,661
Data is an unusual currency; it is not restricted by the same transactional limitations as money or people. In fact, the more that you leverage your data across multiple business use cases, the more valuable it becomes to the organization. And the same can be said about the organization’s analytics. In his session at 19th Cloud Expo, Bill Schmarzo, CTO for the Big Data Practice at EMC, will introduce a methodology for capturing, enriching and sharing data (and analytics) across the organizati...
Sep. 24, 2016 04:15 PM EDT Reads: 1,526
While DevOps promises a better and tighter integration among an organization’s development and operation teams and transforms an application life cycle into a continual deployment, Chef and Azure together provides a speedy, cost-effective and highly scalable vehicle for realizing the business values of this transformation. In his session at @DevOpsSummit at 19th Cloud Expo, Yung Chou, a Technology Evangelist at Microsoft, will present a unique opportunity to witness how Chef and Azure work tog...
Sep. 24, 2016 04:00 PM EDT Reads: 1,475
The vision of a connected smart home is becoming reality with the application of integrated wireless technologies in devices and appliances. The use of standardized and TCP/IP networked wireless technologies in line-powered and battery operated sensors and controls has led to the adoption of radios in the 2.4GHz band, including Wi-Fi, BT/BLE and 802.15.4 applied ZigBee and Thread. This is driving the need for robust wireless coexistence for multiple radios to ensure throughput performance and th...
Sep. 24, 2016 03:45 PM EDT Reads: 1,393
Information technology is an industry that has always experienced change, and the dramatic change sweeping across the industry today could not be truthfully described as the first time we've seen such widespread change impacting customer investments. However, the rate of the change, and the potential outcomes from today's digital transformation has the distinct potential to separate the industry into two camps: Organizations that see the change coming, embrace it, and successful leverage it; and...
Sep. 24, 2016 03:00 PM EDT Reads: 1,012
I'm a lonely sensor. I spend all day telling the world how I'm feeling, but none of the other sensors seem to care. I want to be connected. I want to build relationships with other sensors to be more useful for my human. I want my human to understand that when my friends next door are too hot for a while, I'll soon be flaming. And when all my friends go outside without me, I may be left behind. Don't just log my data; use the relationship graph. In his session at @ThingsExpo, Ryan Boyd, Engi...
Sep. 24, 2016 02:15 PM EDT Reads: 1,178
The Internet of Things can drive efficiency for airlines and airports. In their session at @ThingsExpo, Shyam Varan Nath, Principal Architect with GE, and Sudip Majumder, senior director of development at Oracle, will discuss the technical details of the connected airline baggage and related social media solutions. These IoT applications will enhance travelers' journey experience and drive efficiency for the airlines and the airports. The session will include a working demo and a technical d...
Sep. 24, 2016 02:00 PM EDT Reads: 1,613
SYS-CON Events announced today that China Unicom will exhibit at the 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. China United Network Communications Group Co. Ltd ("China Unicom") was officially established in 2009 on the basis of the merger of former China Netcom and former China Unicom. China Unicom mainly operates a full range of telecommunications services including mobile broadband (GSM, WCDMA, LTE F...
Sep. 24, 2016 01:30 PM EDT Reads: 1,667
Enterprise IT has been in the era of Hybrid Cloud for some time now. But it seems most conversations about Hybrid are focused on integrating AWS, Microsoft Azure, or Google ECM into existing on-premises systems. Where is all the Private Cloud? What do technology providers need to do to make their offerings more compelling? How should enterprise IT executives and buyers define their focus, needs, and roadmap, and communicate that clearly to the providers?
Sep. 24, 2016 01:00 PM EDT Reads: 1,465
The Transparent Cloud-computing Consortium (abbreviation: T-Cloud Consortium) will conduct research activities into changes in the computing model as a result of collaboration between "device" and "cloud" and the creation of new value and markets through organic data processing High speed and high quality networks, and dramatic improvements in computer processing capabilities, have greatly changed the nature of applications and made the storing and processing of data on the network commonplace.
Sep. 24, 2016 12:00 PM EDT Reads: 724
SYS-CON Events announced today that SoftLayer, an IBM Company, has been named “Gold Sponsor” of SYS-CON's 18th Cloud Expo, which will take place on June 7-9, 2016, at the Javits Center in New York, New York. SoftLayer, an IBM Company, provides cloud infrastructure as a service from a growing number of data centers and network points of presence around the world. SoftLayer’s customers range from Web startups to global enterprises.
Sep. 24, 2016 12:00 PM EDT Reads: 722
Digital innovation is the next big wave of business transformation based on digital technologies of which IoT and Big Data are key components, For example: Business boundary innovation is a challenge to excavate third-party business value using IoT and BigData, like Nest Business structure innovation may propose re-building business structure from scratch, as Uber does in the taxicab industry The social model innovation is also a big challenge to the new social architecture with the design fr...
Sep. 24, 2016 11:45 AM EDT Reads: 1,014
Fact is, enterprises have significant legacy voice infrastructure that’s costly to replace with pure IP solutions. How can we bring this analog infrastructure into our shiny new cloud applications? There are proven methods to bind both legacy voice applications and traditional PSTN audio into cloud-based applications and services at a carrier scale. Some of the most successful implementations leverage WebRTC, WebSockets, SIP and other open source technologies. In his session at @ThingsExpo, Da...
Sep. 24, 2016 11:15 AM EDT Reads: 1,441
In his session at @DevOpsSummit at 19th Cloud Expo, Robert Doyle, lead architect at eCube Systems, will examine the issues and need for an agile infrastructure and show the advantages of capturing developer knowledge in an exportable file for migration into production. He will introduce the use of NXTmonitor, a next-generation DevOps tool that captures application environments, dependencies and start/stop procedures in a portable configuration file with an easy-to-use GUI. In addition to captu...
Sep. 24, 2016 11:00 AM EDT Reads: 940